NEJM-Published Phase 1 ATTR Data Fails to Stem Intellia’s 46% Stock Decline

Introduction

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in November 2014, the company utilizes CRISPR/Cas9 genome editing to develop one-time treatments aimed at severe and life-threatening diseases. Intellia’s proprietary lipid nanoparticle delivery system facilitates in vivo editing of disease-causing genes, while its ex vivo programs utilize engineered cells to target oncology and autoimmune conditions.

Corporate Structure

Intellia employs between 501 and 1,000 professionals across research, development, manufacturing, and support functions. The organization was established by both academic founders, including Nobel laureate Jennifer Doudna, and industry leaders, and it maintains collaborations with Regeneron Pharmaceuticals and Novartis. Its public shares trade on the NASDAQ Global Select Market under the ticker NTLA.

CRISPR technology by Zuzanna Adamczyk

Developments and News

On August 7, 2025, Intellia filed its quarterly report on Form 10-Q for the period ended June 30, 2025, addressing its ongoing investments in research and development. On September 25, 2025, the company submitted an 8-K current report (Acc-no 0001193125-25-217484), followed by another 8-K on October 27, 2025 (Acc-no 0001193125-25-250757), primarily providing corporate updates under Items 7.01, 8.01, and 9.01. On October 20, 2025, Intellia announced data from its Phase 1 study of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy, with results subsequently published in the NEJM Group.

Financial and Strategic Analysis

As of October 27, 2025, Intellia’s shares closed at $13.71, reflecting a 46.45% decline year-to-date. Trading volume on that day reached 2,021,611 shares, and the company’s market capitalization was approximately $2.2 billion. Over the trailing twelve months, Intellia reported revenue of $52.9 million and a net loss of $480.2 million. As of June 30, 2025, cash and cash equivalents totaled $459.7 million, with a debt-to-equity ratio of 14.34%, and free cash flow recorded as negative $177.8 million. Valuation multiples include a price-to-sales ratio of 39.7 and an enterprise value-to-revenue ratio of 34.8.

Strategically, Intellia advances both wholly owned and partnered in vivo and ex vivo programs. Its lead candidates, NTLA-2001 for ATTR amyloidosis and NTLA-2002 for hereditary angioedema, are currently in Phase 1/2 studies. Collaboration agreements with Regeneron cover hemophilia B and up to ten additional targets, while a partnership with Novartis focuses on CAR-T applications.

Market Position and Industry Context

Intellia operates in the competitive gene editing sector alongside peers such as Editas Medicine and CRISPR Therapeutics. Its in vivo lipid nanoparticle delivery differentiates it from viral-vector approaches, targeting liver-related and systemic disorders. The company addresses high unmet medical needs in rare diseases, and there is increasing regulatory familiarity with CRISPR modalities in shaping market dynamics. A beta of 2.38 suggests the company's share price may be responsive to clinical and regulatory developments.

tl;dr

On October 20, 2025, Intellia published Phase 1 data in the NEJM Group showing editing effects for its ATTR program. Shares traded at $13.71 on October 27, 2025, with a market cap of approximately $2.2 billion and cash reserves of $459.7 million as of June 30, 2025. Future developments include NTLA-2002 Phase 1/2 readouts in hereditary angioedema and ongoing in vivo trial milestones through 2026.